Pfizer Inc. (PFE)
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial
AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield
Pfizer's stock has struggled to recover since the pandemic, but its high dividend yield of 5.9% makes it an attractive option for income investors. The company faces risks from upcoming patent expiries and the impact of rising interest rates on its debt and ability to invest in research and development. Despite these challenges, Pfizer's valuation metrics suggest it is attractively priced, and a dividend discount model estimates a potential upside of over 30% from the current price level.
2 Top Growth Stocks Down 24% and 50% to Buy With $100
While healthcare is broadly resilient in times of economic stress, each company needs its own evaluation. Pfizer is dealing with a period of transition, but its business has only been bolstered by pandemic successes.
